Literature DB >> 31111641

Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice.

Conghua Song1,2,3,4, Xing Qian1, Yin Zhu1,2,3, Xu Shu1,2,3, Yanping Song1,2,3, Zhijuan Xiong1, Jianfang Ye1, Tao Yu1, Ling Ding1, Hui Wang1, Nonghua Lu1,2,3, Yong Xie1,2,3.   

Abstract

BACKGROUND & AIMS: The eradication rate of Helicobacter pylori (H pylori) has decreased largely because of the antibiotic resistance. We aimed to evaluate the effectiveness and safety of furazolidone-containing quadruple regimens for H pylori eradication.
METHODS: This was an observational study of furazolidone-containing quadruple regimens for H pylori infection in real-world settings. Data sets were collected from the medical records and telephone interviews of patients referred to a specialist clinic for suspected H pylori reinfection from January 1, 2015, to January 1, 2018, at the First Affiliated Hospital of Nanchang University. Main outcome measures were the eradication rate and adverse reactions during medication.
RESULTS: Among 584 patients with H pylori infection that met the inclusion criteria, 561 (96.1%) were treated for the first time, 19 (3.3%) had one, and 4 (0.5%) had two or more prior to furazolidone-containing quadruple regimens. The eradication rates for 10-day and 14-day regimens were 93.7% (95% CI: 91.5%-95.9%) vs 98.2% (95% CI: 95.6%-99.3%), respectively (P = 0.098). Adverse drug reactions occurred in 8.2% (48/584) with abdominal discomfort being the most common symptom. Overall adverse events with 10-day regimens were lower than 14-day regimens (6.1% vs 17.4%, P < 0.001). Logistic regression analysis indicated that poor adherence (adjusted odds ratio [AOR] = 46.5, 95% CI: 9.7-222.4) was correlated with failed eradication. Adverse drug reactions during medication were related to smoking and tobacco status, alcohol intake history, regimens combined with tetracycline, and poor adherence (all P < 0.05).
CONCLUSIONS: Furazolidone-containing quadruple regimens proved both safe and highly effective in a real-world setting.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; adverse drug reactions; eradication rate; furazolidone; real-world study

Mesh:

Substances:

Year:  2019        PMID: 31111641     DOI: 10.1111/hel.12591

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  6 in total

Review 1.  Emphasizing the importance of successful eradication of Helicobacter pylori on initial treatment.

Authors:  Zishao Zhong; Bingjie Zhan; Baohui Xu; Hengjun Gao
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

2.  Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.

Authors:  Jing Liu; Chao-Ran Ji; Yue-Yue Li; Chen Qiao; Jun-Nan Hu; Meng Wan; Min-Juan Lin; Bo-Shen Lin; Juan Wang; Jing Zha; Li-Xiang Li; Xiu-Li Zuo
Journal:  Clin Transl Gastroenterol       Date:  2021-08-16       Impact factor: 4.488

Review 3.  Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.

Authors:  Akiko Shiotani; Priya Roy; Hong Lu; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

4.  Risk factors of furazolidone-associated fever.

Authors:  Jiali Zhang; Chunling Rong; Chenyang Yan; Jie Chen; Wenjun Yang; Lingyan Yu; Haibin Dai
Journal:  PLoS One       Date:  2022-04-08       Impact factor: 3.240

5.  Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection.

Authors:  Airu Liu; Yuxin Wang; Yingxiao Song; Yiqi Du
Journal:  Saudi J Gastroenterol       Date:  2020 Mar-Apr       Impact factor: 2.485

6.  Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.

Authors:  Junxian Wang; Yuping Cao; Wei He; Xiaoping Li
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.